Understanding how a specific protein affects insulin secretion in diabetes
NBCe1-mediated Regulation of HCO3- is a Novel Mechanism Underlying Metabolic Reprogramming and Cystogenesis
This study is looking at a protein called NBCe1B to see how it affects insulin release from the pancreas in people with Type 2 diabetes, and it hopes to find out if blocking this protein can help improve insulin levels and blood sugar control.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Broad Institute, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11052507 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called NBCe1B in the regulation of insulin secretion from pancreatic beta cells, particularly in the context of Type 2 diabetes mellitus (T2DM). The study aims to understand how changes in the function of this protein can lead to metabolic reprogramming and affect the ability of beta cells to secrete insulin in response to glucose. By using advanced techniques like single-cell transcriptomics, the researchers will explore the mechanisms behind these changes and test whether inhibiting NBCe1B can improve insulin secretion and glucose tolerance in diabetic models. This research could provide insights into new therapeutic strategies for managing diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with Type 2 diabetes who experience issues with insulin secretion.
Not a fit: Patients with Type 1 diabetes or those without any form of diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve insulin secretion and glucose control in patients with Type 2 diabetes.
How similar studies have performed: Other research has shown promising results in targeting metabolic pathways in diabetes, suggesting that this approach may also yield beneficial outcomes.
Where this research is happening
Cambridge, United States
- Broad Institute, INC. — Cambridge, United States (Active)
Researchers
- Principal investigator: Brown, Matthew — Broad Institute, INC.
- Study coordinator: Brown, Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.